

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**Olaparib for previously treated BRCA-mutation positive  
hormone-relapsed metastatic prostate cancer  
Rapid review of TA831**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final appraisal determination**

1. Have any additional potential equality issues been raised during the rapid review, and, if so, how has the committee addressed these?

No additional issues were raised.

2. If the recommendations have changed after rapid review, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the new recommendation remove barriers to access.

3. If the recommendations have changed after rapid review, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after rapid review, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes. The description of equality issues was described in section 3.27 of the FAD.

**Approved by Associate Director (name):** Henry Edwards

**Date:** 28/03/2023